Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 557 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritation Clear all
Completed Not applicable Interventional

Smartphone Training for Attention Regulation for IBS

NCT05083091
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness and Attention Training, Mindfulness training, Coping Condition
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 13, 2026, 11:14 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2008 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavior Therapy for Irritability in Autism

NCT04654260
View directory record Official record
Conditions
Autism Spectrum Disorder, Irritability, Disruptive Behavior, Anger, Aggression, Asperger Syndrome, Pervasive Developmental Disorder
Interventions
Behavioral Therapy for Irritability in Autism, Psychoeducation and Supportive Therapy (PST)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 13, 2026, 11:14 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

NCT07794150
View directory record Official record
Conditions
Menopause, Healthy Female Participants
Interventions
Estradiol/Levonorgestrel Transdermal System
Drug
Lead sponsor
Corium Innovations, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
View directory record Official record
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional

Well-being in IBS: Strengths and Happiness (WISH)

NCT05289089
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Positive Psychology Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)

NCT04905524
View directory record Official record
Conditions
Depression, Anxiety, IBS - Irritable Bowel Syndrome
Interventions
VIOME Precision Nutrition Program
Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes

NCT02854137
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987521, Control
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional

Sex Differences in Effectiveness of CBT on IBS Project 3

NCT05155631
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
COGNITIVE BEHAVIORAL THERAPY
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 13, 2026, 11:14 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch

NCT04624867
View directory record Official record
Conditions
Cumulative Irritation and Sensitization
Interventions
HP-1050 Patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional

SMART Program in Irritable Bowel Syndrome (IBS)

NCT03454386
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Stress Management and Resilience Training Program, Self-Management Stress Reduction Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 13, 2026, 11:14 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT07545772
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

NCT01313728
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Tretinoin Gel, Tretinoin Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional

Symptom Management for Irritable Bowel Syndrome

NCT02079857
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Standard protocol, Individualized protocol, Sham acupuncture/Placebo moxa
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 13, 2026, 11:14 AM EDT
Withdrawn Not applicable Interventional

Treatment Resistant Epilepsy and N-Acetyl Cysteine

NCT02054949
View directory record Official record
Conditions
Autistic Disorder, Seizures, Irritability
Interventions
N-Acetyl Cysteine (NAC)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT01880424
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Placebo, Linaclotide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
52
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 13, 2026, 11:14 AM EDT
Recruiting Phase 2 Interventional

Fecal Microbiota Transplantation for IBS

NCT05776914
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation
Biological
Lead sponsor
Madhusudan (Madhu) Grover, MBBS
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Not applicable Interventional

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Personalized Dietary Advice
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 13, 2026, 11:14 AM EDT
Recruiting Not applicable Interventional

Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children

NCT07222943
View directory record Official record
Conditions
Functional Abdominal Pain Disorders, Irritable Bowel Syndrome (IBS), Functional Gastrointestinal Disorders (FGIDs), Gastrointestinal and Digestive Disorder, Abdominal Pain/ Discomfort, Pain, Functional Dyspepsia
Interventions
Guided Imagery Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 13, 2026, 11:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomarkers for Intestinal Permeability in Patients With Constipation

NCT02246647
View directory record Official record
Conditions
Intestinal Diseases, Irritable Bowel Syndrome, Constipation
Interventions
Permeability measurement, Esophagogastroduodenoscopy, Flexible sigmoidoscopy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 13, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03977155
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
BOS-589, Placebo
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 13, 2026, 11:14 AM EDT